Indivior Pharmaceuticals, Inc. filings document formal disclosures for a Nasdaq-listed specialty pharmaceutical company focused on buprenorphine-based treatments for opioid use disorder. Its 8-K reports cover operating results, Regulation FD presentations, material agreements, capital-structure matters, and financing events, including the 0.625% Convertible Senior Notes due 2031.
Indivior’s proxy materials describe shareholder voting matters, board and governance practices, executive compensation, and the company’s operating roadmap for SUBLOCADE growth. The filing record also includes common-stock registration details, financial disclosures tied to its OUD treatment business, share-repurchase activity, and registration-status matters.
Indivior Pharmaceuticals, Inc. stockholders approved the issuance of common shares in connection with the merger contemplated by the Merger Agreement. At the special meeting on October 15, 2026, the proposal received 85,455,705 votes for, 5,563,744 against and 186,733 abstentions. The proposal covered the shares contemplated by the merger, including for compliance with Nasdaq Rule 5635.
As of September 4, 2026, 118,031,934 shares were outstanding and entitled to vote; 91,206,182 shares were present in person or by proxy, representing 77.27% and constituting a quorum. No vote was taken on the separate adjournment proposal because stockholder action was not required.
Indivior Pharmaceuticals, Inc. (INDV) supplemented the joint proxy statement/prospectus for its proposed merger with Supernus Pharmaceuticals. Subject to the merger agreement’s terms and conditions, Indivior’s merger subsidiary would merge into Supernus, which would survive as Indivior’s wholly owned subsidiary; Indivior would then be renamed Supernus, Inc. Each company’s stockholders will hold a special meeting on October 15, 2026.
The supplement revises Cantor Fitzgerald’s valuation disclosures. Its analysis indicated an implied per-share equity value reference range of $50.55 to $59.50 for Supernus and a dividend-adjusted range of $24.20 to $43.90 for Indivior. The Indivior analysis reflects a $1 billion Special Dividend.
Indivior Pharmaceuticals, Inc. filed a supplement to the definitive joint proxy statement/prospectus for its proposed merger with Supernus Pharmaceuticals, Inc. Under the merger agreement, Artemis Merger Sub Inc., Indivior’s wholly owned subsidiary, would merge with and into Supernus; Supernus would survive as Indivior’s wholly owned subsidiary, and Indivior would be renamed Supernus, Inc. The transaction remains subject to the agreement’s conditions. Each company’s special stockholder meeting is scheduled for October 15, 2026.
The updated Cantor Fitzgerald analyses indicate approximate implied per-share equity values of $50.55 to $59.50 for Supernus and a dividend-adjusted range of $24.20 to $43.90 for Indivior. The analyses discount projected cash flows to June 30, 2026, using discount rates of 9.5% to 11.5% for Supernus and 8.0% to 10.0% for Indivior. They assume perpetual cash-flow growth or decline rates from negative 10.0% to positive 3.0% after December 31, 2040. The Indivior analysis adjusts for the $1 billion Special Dividend.
Indivior Pharmaceuticals, Inc. (INDV) is the issuer whose shares are covered by ownership reports from Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. Each lists 6,343,651 shares as beneficially owned, equal to 5.4%, with shared voting and dispositive power over that amount. The shares are held by entities subject to voting control and investment discretion by Millennium Management and/or other investment managers that may be controlled by Millennium Group and Englander. The reporting persons state that this disclosure alone is not an admission of beneficial ownership of securities held by those entities.
Indivior Pharmaceuticals, Inc. (INDV) announced that its board declared a special cash dividend of $8.13 per share of common stock, payable to stockholders of record on October 30, 2026 and to certain equity award holders as their awards vest. Payment of the Special Dividend is subject to and contingent upon the closing of Indivior’s planned merger with Supernus Pharmaceuticals, Inc. If the merger closes as currently expected on November 2, 2026, Indivior anticipates paying the Special Dividend to record holders on or about November 6, 2026. Indivior expects that at least a majority of the Special Dividend will exceed its current and accumulated earnings and profits, so U.S. holders may treat a portion first as a return of capital to their tax basis and then as capital gain.
Indivior Pharmaceuticals, Inc. (INDV) announced that its board has declared a special cash dividend of $8.13 per share of common stock, including $8.13 per share on certain Indivior equity awards. The dividend is payable to holders of record as of October 30, 2026, but only if the pending merger with Supernus Pharmaceuticals, Inc. closes.
The merger, under an existing Merger Agreement, is expected to close on or about November 2, 2026, with the special dividend anticipated to be paid to eligible record holders on or about November 6, 2026. Supernus stockholders will not receive the special dividend on Indivior shares issued as merger consideration. Indivior currently expects at least a majority of the special dividend to exceed its current and accumulated earnings and profits, so U.S. holders may treat that portion first as a return of capital up to basis and then as capital gain.
Indivior Pharmaceuticals, Inc. (INDV) reports that its subsidiary Indivior UK Limited and Reckitt Benckiser Healthcare (UK) Limited signed a Deed of Variation and Termination on September 9, 2026 to accelerate termination of their Copacker Supply Agreement for SUBOXONE and SUBUTEX tablets to January 15, 2027. The Copacker Supply Agreement will remain in effect until that accelerated termination date.
Indivior has identified a new supplier, and its obligations under the new supply agreement will only become enforceable after validation of the new supplier’s manufacturing process; this new agreement is stated as not expected to be material to Indivior Pharmaceuticals, Inc. Under the Deed of Variation and Termination, Reckitt Benckiser will manufacture additional units before the new termination date, and Indivior will pay certain specified costs, including lower-volume, asset disposal, depreciation recovery, redundancy, incentive and potential third-party costs. The aggregate amount of these costs is fixed or capped and is stated as not material to the registrant.
Indivior Pharmaceuticals, Inc. (INDV) is registering common shares to be issued in an all‑stock merger of equals with Supernus Pharmaceuticals, Inc. Under a fixed 1.5401 exchange ratio, each Supernus share will convert into the right to receive 1.5401 Indivior shares plus cash in lieu of fractional shares, and Supernus will become a wholly owned subsidiary of Indivior. Indivior will then be renamed Supernus, Inc. and its shares will trade on Nasdaq Global Select Market under the ticker “SUPN.”
Indivior will declare a one‑time $1.0 billion Special Dividend for its stockholders and certain equity award holders, payable only if the merger closes. If committed debt financing becomes unavailable but all closing conditions are otherwise satisfied, this may be replaced by an Alternative Dividend of $500 million in cash plus $529.5 million of deferred cash rights. After closing, Indivior stockholders are expected to own approximately 56.5% of the combined company on a fully diluted basis, with former Supernus holders owning about 43.5%. Completion requires approval of the share‑issuance proposal by Indivior stockholders and adoption of the merger agreement by Supernus stockholders at virtual special meetings on October 15, 2026, along with regulatory clearances and other customary conditions.
Indivior Pharmaceuticals, Inc. (INDV) has filed an amended Form S-4 to register common stock to be issued in an all-stock merger of equals with Supernus Pharmaceuticals, Inc. Each outstanding Supernus share will be converted into the right to receive 1.5401 Indivior Shares, plus cash in lieu of fractional shares. Supernus will become a wholly owned subsidiary of Indivior, which will be renamed Supernus, Inc., and the combined company’s shares will trade on Nasdaq Global Select Market under the ticker “SUPN.”
Prior to closing, Indivior plans to declare a $1.0 billion Special Dividend for existing Indivior stockholders and certain equity award holders, payable only if the merger closes. In an “Alternative Dividend Scenario” if committed financing is unavailable, the dividend would instead total $1.0295 billion through a $500 million cash payment and $529.5 million in dividend payment rights. After the merger, Indivior stockholders are expected to own about 56.5% of the combined company on a fully diluted basis, with former Supernus holders owning about 43.5%, subject to customary closing conditions, regulatory approvals and stockholder votes at both companies’ special meetings on October 15, 2026.